We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+6.36%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$6.76B
AUM Growth
-$342M
Cap. Flow
-$367M
Cap. Flow %
-5.43%
Top 10 Hldgs %
43.88%
Holding
93
New
7
Increased
14
Reduced
55
Closed
7

Top Buys

Rank Stock Value
1
VERV
Verve Therapeutics
VERV
+$80.4M
2
ZY
Zymergen Inc. Common Stock
ZY
+$60.1M
3
SKIN icon
SkinHealth Systems
SKIN
+$59.8M
4
ONEM
1Life Healthcare
ONEM
+$41.7M
5
LFST icon
Lifestance Health
LFST
+$33.2M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$116M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$96.2M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$85.8M
4
BIIB icon
Biogen
BIIB
+$45.6M
5
BEAM icon
Beam Therapeutics
BEAM
+$38.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.73%
2 Consumer Staples 1.58%
3 Financials 0.69%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
1
Fate Therapeutics
FATE
$291M
$1.12B 16.64%
12,957,222
– –
IGMS
2
DELISTED
IGM Biosciences
IGMS
$285M 4.22%
3,425,455
– –
BEAM icon
3
Beam Therapeutics
BEAM
$3.03B
$264M 3.91%
2,052,506
-480,017
-19% -$38.2M
ARGX icon
4
argenx
ARGX
$64B
$238M 3.52%
790,282
-59,563
-7% -$16.9M
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
$201M 2.97%
20,799,303
-314,811
-1% -$3.07M
ALLK
6
DELISTED
Allakos
ALLK
$189M 2.8%
2,216,996
-202,422
-8% -$20.2M
ADCT icon
7
ADC Therapeutics
ADCT
$146M
$183M 2.71%
7,522,029
+213,611
+3% +$4.96M
STTK icon
8
Shattuck Labs
STTK
$707M
$163M 2.41%
5,619,914
– –
REPL icon
9
Replimune Group
REPL
$1.46B
$161M 2.38%
4,191,512
+73,300
+2% +$2.51M
NVTA
10
DELISTED
Invitae Corporation
NVTA
$157M 2.32%
4,647,393
-204,770
-4% -$6.66M
DCPH
11
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$155M 2.3%
4,244,721
-106,923
-2% -$4.14M
JAZZ icon
12
Jazz Pharmaceuticals
JAZZ
$15.9B
$153M 2.26%
860,101
+30,942
+4% +$5.36M
MDVL
13
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$144M 2.13%
234,495
– –
KRYS icon
14
Krystal Biotech
KRYS
$10.4B
$141M 2.09%
2,072,132
+12,000
+0.6% +$838K
OSH
15
DELISTED
Oak Street Health, Inc.
OSH
$135M 2%
2,302,653
-627,758
-21% -$37.4M
KYMR icon
16
Kymera Therapeutics
KYMR
$9.82B
$123M 1.82%
2,531,508
-71,631
-3% -$3.11M
SGEN
17
DELISTED
Seagen Inc. Common Stock
SGEN
$122M 1.8%
771,385
-165,660
-18% -$24.6M
VERV
18
DELISTED
Verve Therapeutics
VERV
$117M 1.73%
+1,936,530
New +$80.4M
SKIN icon
19
SkinHealth Systems
SKIN
$89.1M
$107M 1.58%
6,353,246
+4,370,497
+220% +$59.8M
CLDX icon
20
Celldex Therapeutics
CLDX
$3.07B
$101M 1.49%
3,012,081
-375,707
-11% -$10.3M
ATRA icon
21
Atara Biotherapeutics
ATRA
$92.3M
$100M 1.48%
257,983
-17,426
-6% -$6.22M
NVRO
22
DELISTED
NEVRO CORP.
NVRO
$98.6M 1.46%
594,732
+77,937
+15% +$12.2M
DXCM icon
23
DexCom
DXCM
$34.3B
$98.4M 1.46%
922,232
+32,400
+4% +$3.11M
LIVN icon
24
LivaNova
LIVN
$4.43B
$93.5M 1.38%
1,111,684
-8,146
-0.7% -$671K
PLRX icon
25
Pliant Therapeutics
PLRX
$68.7M
$91.9M 1.36%
3,156,401
-50,792
-2% -$1.58M
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2021 Portfolio in Review

As of Q2 2021, Redmile Group held 93 positions worth $6.76B, down 4.8% from $7.1B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Redmile Group withdrew a net $367M in Q2 2021, closing 7 positions and reducing 55 holdings. Its most notable exit was Medtronic, an estimated $116M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Redmile Group opened a new position in Verve Therapeutics worth $117M.

  • Redmile Group's largest Q2 2021 buy was Verve Therapeutics: 1,936,530 shares worth $117M.
  • Redmile Group added most to SkinHealth Systems in Q2 2021, an estimated $59.8M increase.
  • Redmile Group's biggest Q2 2021 reduction was Zentalis Pharmaceuticals, cutting an estimated $96.2M.
  • Redmile Group fully exited Medtronic in Q2 2021, selling an estimated $116M.
  • Redmile Group's ten largest holdings make up 44% of its $6.76B portfolio in Q2 2021.
  • Redmile Group opened 7 new positions and closed 7 in Q2 2021.
  • Redmile Group's portfolio value fell 4.8% quarter-over-quarter to $6.76B.

Based on Redmile Group's 13F filing for Q2 2021, filed 16 Aug 2021.